

Psoriasis Overview and Emerging Therapies


Psoriasis – making the diagnosis

Important characteristics:

- Often symmetrical distribution
- Well defined lesions with a characteristic silvery scale
- Extensor surfaces typically affected
- Loss of scale in body folds

Psoriasis Overview


- Psoriasis is an autoimmune condition resulting from chronic activation of the immune system
- Activation of the immune system results in an excess of keratinocytes that mature at a rapid rate
- Usually the skin takes approx. 28 days to renew itself, in patients with psoriasis it only takes ~3-4 days.
- This causes the signs and symptoms characteristic of Psoriasis:
 - Redness
 - Thickened skin
 - Scaling



Mentzer A et al. JAAD 2008;58:626-50; Pictures on-line at google images

Psoriasis Overview

- Occurs most commonly in late teens or early 50's
- Most common type of psoriasis is plaque psoriasis¹
- Prevalence in Australia is 1-3%²
- Possible genetic association – family history¹
- Up to 30% of patients with Psoriasis can develop Psoriatic Arthritis (PsA)³
- In 75% of cases, psoriasis precedes the joint disease in PsA⁴




1. Mentzer A et al. JAAD 2008;58:626-50. 2. Raychaudhuri et al., JEADV 2001; 15:20-23. 3. Gottlieb A et al. JAAD 2008;58:851-64. 4. www.australiandoc.com.au 19-02-2010; Pictures on-line at google images

Psoriasis is a hereditary disease

- A predisposing genotype for psoriasis can be inherited
- One-third of patients with psoriasis report relatives with disease
- Inheritance is polygenic and psoriasis is a multifactorial disease


Psoriasis the commonest autoimmune condition to affect humans

- Previously psoriasis was thought to be due to an abnormal response to injury
- Evidence now that *psoriasis is a T- cell mediated autoimmune disorder*




Psoriasis - triggers & aggravating factors

- **Infection**
 - Streptococcal
 - HIV
- **Drugs**
 - Lithium
 - B-blockers
 - Antimalarials
 - Interferon
 - ACE inhibitors
 - Corticosteroid withdrawal
- **Physical injury**
- **(Koebner phenomenon)**
- **Stress**
- **Excessive alcohol**



Types of psoriasis

Morphology	Specific Sites
<ul style="list-style-type: none"> • Plaque • Guttate • Erythrodermic • Pustular • Flexural 	<ul style="list-style-type: none"> • Scalp • Palmo-plantar • Nail • Flexural • Genital



Nail psoriasis

- Onycholysis
- Pitting
- "Oil drop" spots
- Subungual hyperkeratosis
- Thickening & dystrophic nail plate
- Periungal psoriasis

Psoriasis Co-morbidities

<ul style="list-style-type: none"> ■ PsA ■ obesity ■ hypertension ■ diabetes ■ hyperlipidemia ■ metabolic syndrome ■ cardiovascular disease ■ Crohn's disease ■ lymphoma ■ multiple sclerosis ■ increased mortality 	}	immunopathogenic
<ul style="list-style-type: none"> ■ smoking ■ alcoholism ■ anxiety ■ depression 	}	psychosocial

Guenther L & Gulliver W. J Cutaneous Med Surg 2009;13(Suppl2):S77-87.

How to assess psoriasis

- **Body Surface Area**
- **PASI score**
 - A scoring system based on erythema, scale, thickness and area
 - Possible scores 0 to 70
 - Used by PBS for access to biologic therapies
 - PASI > 15 severe psoriasis
- **Quality of Life (DLQI)***
 - A validate research tool of ten questions
 - Possible score 0 to 30
 - DLQI > 5 indicate significant life impact

*Prof Andrew Finlay, Wales College of Medicine, Cardiff University, United Kingdom

Psoriasis Treatments

Four Major Types of Treatment

- Topical therapies
- Phototherapy
- Systemic therapies
- Biologic therapies

www.australiandoctor.com.au 19-02-2010

Topical Therapies

- Corticosteroids
- Vitamin D analogues
- Retinoids
- Coal tar
- Dithranol

www.australiandoctor.com.au 19-02-2010

Phototherapy

- UVB
 - Narrowband ultraviolet B radiation
- PUVA (photochemotherapy)
 - Ultraviolet A combined with light-sensitising drug psoralen

www.australiandoctor.com.au 19-02-2010


Systemic immunosuppressive therapies

- Methotrexate
- Acitretin
- Cyclosporin

www.australiandoctor.com.au 19-02-2010


Biological agents

Remicade




Chimeric monoclonal anti-TNF-α

Humira




Human monoclonal anti-TNF-α

Enbrel



Human p75 TNF receptor II fused protein

Stelara



Human recombinant anti-p40 antibody

Anti-TNF **Anti-IL12/23**

Nestle et al., 2009, NEJM, 361: 5, pg 505 (permission to use this image granted by NEJM)

Biological Agents in Psoriasis

Agent	Dose	t 1/2	PASI 75	Experience*	Indications
Adalimumab	40 mg fortnightly	10-20 days	71 % (week 16)	9 years	Ps, RA, AS, PsA, JIA, CD
Etanercept	25 mg Biweekly or 50mg weekly	3.3 days	55 % (week 24)	13 years	Ps, RA, AS, PsA, JIA
Infliximab	5 mg 8 weekly	8 - 9.5 days	80 % (week 10)	13 years	Ps, RA, AS, PsA, CD, UC, FCD, PCD
Ustekinumab	45 mg 12 weekly, 90 mg in patients > 100kg	15-32 days	67 % (45mg) 66% (90mg) (week 12)	3 years	Ps

*Experience based on time since product registration including all indications. Based on data from REVEAL, Papp et al., 2005, EXPRESS, PNOGENE I. Etanercept Product Information, v CD628.0. Infliximab Product Information, v 15. Ustekinumab Product Information, v CCG506217. Ps = Psoriasis, RA = Rheumatoid Arthritis, AS = Ankylosing Spondylitis, PsA = Psoriatic Arthritis, JIA = Juvenile Idiopathic Arthritis, CD = Crohn's Disease, UC = Ulcerative Colitis, FCD = Fistulising Crohn's Disease, PCD = Psoriatic Crohn's Disease.

TOPICAL THERAPIES■ **Topical corticosteroids**

Potent/very potent- trunk, limbs, scalp

Mild – face, flexures

Combination with non- steroidal topical therapies
<100 g of moderate/high potency steroids/month

■ **Vitamin D3 analogs**

Calcipotriol, Tacalcitol, Calcitriol

100g/week Face and flexures to be avoided

■ **Coal tar**

LPC +SA

Staining of skin and clothing, local skin irritation

■ **Dithranol**

Dithranol in zinc oxide (Lassar's paste)

0.1- 0.6%

Short contact

■ **Tazarotene****Treatment of other forms of Psoriasis**■ **Guttate psoriasis**

Emollients

Topical steroids

Vitamin D3 analogs

NBUVB

■ **Chronic palmar- plantar psoriasis**

Potent/very potent steroids +/- occlusion

■ **Pustular and Erythrodermic psoriasis**

Potentially life threatening spectrum of diseases

In

SPECIAL SITES■ **Scalp psoriasis**

Formulation – lotions, gels, shampoos

Mild- to – moderate scalp psoriasis

Coal tar shampoos, Ketoconazole

Corticosteroids (potent/very potent)

Calcipotriol +betamethasone dipropionate gel

Severe scalp psoriasis

Thick, adherent scale should be removed gently

15-30% salicylic acid in mineral oil

Tar pomade (LPC 10%+SA 6% in acq cream/sorbolene)

Scalp psoriasis

Salicylic acid 30% in mineral oil left on for 15 mins to loosen the scales.

Patient is then asked to comb out the scales with a wide-toothed comb.

Patient is then to apply a tar pomade cream to be left on for 3 hours

Tar pomade consists of LPC 10% + SA 6% in sorbolene/acq cream.

This is then washed off using a tar based shampoo before going to bed.

Flexural sites, the face and genitalia■ **FACE**

Mild steroid +/- coal tar solution/antifungal agents

Tacrolimus, pimecrolimus

Methylprednisolone aceponate (Advantan)

■ **FLEXURAL**

Sec infection- bacterial/candidal

Topical steroid creams

Tacro/pimecrolimus

Weak antiseptic soaks (Burrows 1:40)

TAR Preparations

6% LPC, 3% Sal Acid in Aqueous cream/
Sorbolene
6% LPC, 3% Sal Acid in WSP
10% LPC, 6% Sal Acid in Aqueous
cream/Sorbolene/WSP
1%-2% Crude Coal Tar in Aqueous
cream
5% Crude Coal Tar in Aqueous cream
Tar/Dithranol Cream (10% LPC,
Dithranol 0.1%, 6% Sal Acid in
Sorbolene)

DITHRANOL

■ Lower concentrations in long contact regimen

*Dithranol 0.1 to 2% with Salicylic acid 2-5% in WSP
Topically to lesions with care once daily*

■ Higher concentrations in short – contact regimen

*Dithranol 0.5 to 2% with Salicylic acid 2-5% in yellow soft
paraffin, topically to lesions with care once daily for 30
minutes before washing off.*

DITHRANOL

- 0.1%/0.2/0.5/1% Dithranol, 3% Sal Acid
Tar in WSP
- 2% Dithranol, 3% Sal Acid Tar in WSP
- 5% Dithranol, 3% Sal Acid Tar in WSP
- 0.5%- 2% Dithranol, in Lassar's Paste

Nail psoriasis

General measures

Treatment of sec infection

Daivobet gel- nail folds

Very potent topical steroids – Clobetasol 0.05%

I/L KA 10mg/ml 1: 1 diluted with Xylocaine- PNF

MTX

Biologic agents

PSORIASIS IN CHILDREN

15% of cases of psoriasis in children <15yrs

Infancy – nappy rash

Flexural+ genital involvement

Guttate psoriasis

Treatment

Topical steroids

Coal tar

Calcipotriol

NBUVB

PREGNANCY

■ Topical steroids

Category A

Hydrocortisone

Triamcinolone

Diprosone (betamethasone dipropionate)

Betnovate (betamethasone valerate)


■ Phototherapy

NBUVB


Clinical diagnosis

- 19 yo University student
- Widespread non itchy rash trunk limbs for 12 days
- New spots appearing
- Very upset at the appearance and worried she is contagious
- PH tonsillitis 2 weeks ago treated with Augmentin
- Family history – mother bad dandruff, maternal grandfather had a chronic rash but details??

Jenny



Jenny



Clinical diagnosis

- Differential diagnoses
- triggers
- investigations
- Management options
- Prognosis